Torray Funds has liquidated its entire position in Vertex Pharmaceuticals (VRTX), according to a recent quarterly filing. The fund sold all 15,210 of its shares, which were valued at approximately $7.56 million as of the September 30, 2026 reporting period. This disclosure, made in a 13F filing on October 30, 2026, reflects trades made in the preceding quarter and does not represent a real-time transaction.
This move marks a complete exit from a position that previously constituted about 1.02% of Torray Funds' reported portfolio. The sale comes as Vertex recently raised its revenue outlook following an acquisition, although it also reported a decrease in third-quarter profit. Torray Funds has not publicly commented on its reasons for divesting from the pharmaceutical company.